unknown
Stage
About
Ability develops precision biotherapeutic antibodies using its proprietary AI-driven discovery platform AbiLeap™ to create novel immune cell-targeting therapies for autoimmune, inflammatory diseases, and cancer.
Explore Ability's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.